178 related articles for article (PubMed ID: 17049192)
1. Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis.
El-Ridy MS; Mostafa DM; Shehab A; Nasr EA; Abd El-Alim S
Int J Pharm; 2007 Feb; 330(1-2):82-8. PubMed ID: 17049192
[TBL] [Abstract][Full Text] [Related]
2. Niosomal encapsulation of the antitubercular drug, pyrazinamide.
El-Ridy MS; Abdelbary A; Nasr EA; Khalil RM; Mostafa DM; El-Batal AI; Abd El-Alim SH
Drug Dev Ind Pharm; 2011 Sep; 37(9):1110-8. PubMed ID: 21417612
[TBL] [Abstract][Full Text] [Related]
3. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis.
Byrne ST; Denkin SM; Zhang Y
J Antimicrob Chemother; 2007 Feb; 59(2):313-6. PubMed ID: 17185297
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide.
Gangadharam PR; Geeta N; Hsu YY; Wise DL
Int J Tuberc Lung Dis; 1999 Jun; 3(6):515-20. PubMed ID: 10383065
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
Pandey R; Khuller GK
J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
[TBL] [Abstract][Full Text] [Related]
6. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis.
Gaspar MM; Cruz A; Penha AF; Reymão J; Sousa AC; Eleutério CV; Domingues SA; Fraga AG; Filho AL; Cruz ME; Pedrosa J
Int J Antimicrob Agents; 2008 Jan; 31(1):37-45. PubMed ID: 18006283
[TBL] [Abstract][Full Text] [Related]
7. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
Sharma A; Sharma S; Khuller GK
J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
[TBL] [Abstract][Full Text] [Related]
8. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.
Ahmad Z; Sharma S; Khuller GK
Int J Antimicrob Agents; 2005 Oct; 26(4):298-303. PubMed ID: 16154726
[TBL] [Abstract][Full Text] [Related]
9. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential.
Ahmad Z; Pandey R; Sharma S; Khuller GK
Indian J Chest Dis Allied Sci; 2006; 48(3):171-6. PubMed ID: 18610673
[TBL] [Abstract][Full Text] [Related]
10. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
Singh S; Mohan B
Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
[TBL] [Abstract][Full Text] [Related]
11. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
Pandey R; Sharma S; Khuller GK
Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
[TBL] [Abstract][Full Text] [Related]
12. Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice.
de Steenwinkel JE; van Vianen W; Ten Kate MT; Verbrugh HA; van Agtmael MA; Schiffelers RM; Bakker-Woudenberg IA
J Antimicrob Chemother; 2007 Nov; 60(5):1064-73. PubMed ID: 17846106
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.
Gopal P; Grüber G; Dartois V; Dick T
Trends Pharmacol Sci; 2019 Dec; 40(12):930-940. PubMed ID: 31704175
[TBL] [Abstract][Full Text] [Related]
14. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
Pandey R; Khuller GK
Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of pyrazinamide in elephants.
Zhu M; Maslow JN; Mikota SK; Isaza R; Dunker F; Riddle H; Peloquin CA
J Vet Pharmacol Ther; 2005 Oct; 28(5):403-9. PubMed ID: 16207301
[TBL] [Abstract][Full Text] [Related]
16. The potential of azole antifungals against latent/persistent tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 May; 258(2):200-3. PubMed ID: 16640573
[TBL] [Abstract][Full Text] [Related]
17. Free versus liposome-entrapped streptomycin sulfate in treatment of infections caused by Salmonella enteritidis.
Khalil RM; Murad FE; Yehia SA; El-Ridy MS; Salama HA
Pharmazie; 1996 Mar; 51(3):182-4. PubMed ID: 8900871
[TBL] [Abstract][Full Text] [Related]
18. Pyrazinamide.
Tuberculosis (Edinb); 2008 Mar; 88(2):141-4. PubMed ID: 18486055
[No Abstract] [Full Text] [Related]
19. In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.
Rao SS; Raghunathan R; Ekambaram R; Raghunathan M
Int J Antimicrob Agents; 2009 Nov; 34(5):451-3. PubMed ID: 19625168
[TBL] [Abstract][Full Text] [Related]
20. Modulation of reticuloendothelial activity with liposomes.
Hojo H; Hoshino Y; Kurita T; Hashimoto Y
Res Commun Chem Pathol Pharmacol; 1985 Mar; 47(3):373-85. PubMed ID: 3992015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
